Location History:
- Upsala, SE (1993)
- Uppsala, SE (2000 - 2009)
Company Filing History:
2 out of 525 
2 out of 7 Years Active: 1993-2009
Title: Lena Claesson-Welsh: Innovator in Angiogenesis Research
Introduction
Lena Claesson-Welsh is a prominent inventor based in Uppsala, Sweden. She has made significant contributions to the field of biomedical research, particularly in the study of histidine-rich glycoproteins and their applications in inhibiting angiogenesis. With a total of four patents to her name, Claesson-Welsh has established herself as a key figure in her area of expertise.
Latest Patents
Her latest patents focus on histidine-rich glycoprotein (HRGP) polypeptides and their uses. The inventions include methods for inhibiting angiogenesis through the administration of HRGP polypeptides. Additionally, these patents encompass pharmaceutical compositions and articles of manufacture that comprise HRGP polypeptides, antibodies, and receptors that bind to HRGP polypeptides. They also cover HRGP-depleted plasma, polynucleotides, vectors, and host cells that encode HRGP polypeptides.
Career Highlights
Throughout her career, Claesson-Welsh has worked with notable organizations such as the Ludwig Institute for Cancer Research Limited and Innoventus Project AB. Her work has been instrumental in advancing the understanding of angiogenesis and its implications in various medical conditions.
Collaborations
Lena Claesson-Welsh has collaborated with esteemed colleagues, including Carl-Henrik Heldin and Anna-Karin Olsson. These partnerships have further enriched her research and contributed to the development of innovative solutions in her field.
Conclusion
Lena Claesson-Welsh is a distinguished inventor whose work in histidine-rich glycoproteins has the potential to impact medical research significantly. Her contributions to the field of angiogenesis research highlight her role as a leading innovator in biomedical science.